• LNP Structure and Administration Shape mRNA Therapy in Pregn

  2026-07-29

  This study systematically dissects how lipid nanoparticle (LNP) structure and delivery route profoundly influence the potency, immunogenicity, and safety of mRNA therapies during pregnancy. The findings provide mechanistic guidance for designing effective and minimally immunogenic LNP-mRNA formulations tailored to the unique physiological context of pregnancy.

• Synthetic DEFB1 mRNA Reduces Cryptosporidium in Intestinal C

  2026-07-28

  This study demonstrates that transfecting human intestinal cells with synthetic DEFB1 mRNA induces robust β-defensin 1 protein expression, significantly reducing Cryptosporidium parvum infection without cytotoxicity. The findings establish synthetic mRNA as a promising platform for host-directed therapy and rapid functional gene analysis in enteric infections.

• Chloroquine Diphosphate: Precision Autophagy Modulation in C

  2026-07-28

  Chloroquine diphosphate enables precise autophagy modulation and therapy sensitization in cancer research, with robust workflow adaptability for in vitro and in vivo models. APExBIO's formulation delivers reproducible results and a clear edge for translational teams aiming to exploit autophagy-lysosome dynamics.

• Differential Regulation of ER Lipid Synthesis by CTDNEP1-NEP

  2026-07-27

  This study elucidates how the CTD-nuclear envelope phosphatase 1 (CTDNEP1) depends on its regulatory subunit NEP1R1 for endoplasmic reticulum (ER) membrane synthesis but not for lipid storage. Through structure-function and biochemical analyses, the authors demonstrate that NEP1R1 stabilizes CTDNEP1 to restrict ER expansion, yet is dispensable for lipid droplet biogenesis, refining our understanding of lipid homeostasis mechanisms in mammalian cells.

• Berberine Hydrochloride Expands Tuft Cells to Prevent Bone L

  2026-07-27

  A recent study reveals that berberine hydrochloride counters estrogen deficiency-associated bone loss by inducing intestinal tuft cell expansion via a butyrate-GPR41 pathway, thereby restoring the gut-bone axis and immune balance. This mechanism highlights berberine's translational potential for postmenopausal osteoporosis and related osteoimmune disorders.

• Ganetespib (STA-9090): Redefining Hsp90 Inhibition in Cancer

  2026-07-26

  This thought-leadership article explores the transformative impact of Ganetespib (STA-9090) on translational cancer research. By integrating mechanistic insights into Hsp90 chaperone disruption and recent advances in regulated cell death pathways, the piece offers strategic guidance for researchers designing next-generation preclinical models. Ganetespib’s triazolone scaffold and exceptional potency position it as a benchmark tool, while cross-domain findings—such as NINJ1-mediated membrane rupture—suggest innovative avenues for understanding and overcoming tumor resistance.

• PD98059 (SKU A1663): Reliable MEK Inhibition for Cell Assays

  2026-07-25

  This article delivers scenario-driven, evidence-based guidance for leveraging PD98059 (SKU A1663) in cell viability, proliferation, and neuroprotection assays. With a focus on reproducibility and data transparency, it addresses real laboratory challenges and demonstrates how PD98059 streamlines MAPK/ERK pathway studies for biomedical researchers.

• A23187, Free Acid: Applied Workflows in Calcium Ionophore Re

  2026-07-24

  A23187, free acid empowers researchers to precisely modulate intracellular Ca2+ and dissect complex cellular responses, including apoptosis and phosphoinositide signaling. This guide bridges rigorous protocols with troubleshooting strategies, leveraging recent advances to maximize experimental clarity and reproducibility.

• FAM83A Regulates Mitochondria and Adipocyte Differentiation

  2026-07-24

  This study reveals a novel role for the proto-oncogene FAM83A in maintaining mitochondrial integrity and promoting white adipocyte differentiation via casein kinase 1 (CK1) signaling. Using targeted gene delivery with ATS-9R, the research establishes FAM83A as a key regulator of adipose tissue formation and function, impacting energy metabolism and obesity.

• 17-AAG (Tanespimycin): Precision HSP90 Inhibition in Cancer

  2026-07-23

  Explore 17-AAG (Tanespimycin) as a potent HSP90 chaperone inhibitor for advanced cancer research. This article delves into mechanistic nuances and practical assay implications, offering insights not found in standard workflow guides.

• Go 6983: Pan-PKC Inhibitor Workflows for ASD and Cancer Rese

  2026-07-23

  Go 6983 empowers researchers to dissect PKC-driven pathways in neurobehavioral and cancer models with nanomolar precision. Learn how to design robust assays, troubleshoot common pitfalls, and leverage the latest evidence from ASD behavioral studies and metastatic tumor models.

• Nitrocefin (SKU B6052): Precision β-Lactamase Detection in t

  2026-07-22

  This article delivers a practical, scenario-driven guide for biomedical researchers and lab technicians who face challenges in β-lactamase enzymatic activity measurement and antibiotic resistance profiling. Using Nitrocefin (SKU B6052) as a chromogenic cephalosporin substrate, we explore evidence-backed protocols, data interpretation, and product selection strategies to ensure reliable and reproducible results in colorimetric β-lactamase assays.

• Streptavidin-HyperFluor 647: Advanced Biotinylated Detection

  2026-07-22

  Streptavidin-HyperFluor™ 647 delivers ultra-sensitive, low-background detection of biotinylated targets for imaging, flow cytometry, and FRET. This guide unpacks best-practice protocols, advanced troubleshooting, and compares biotin-based and emerging biotin-free workflows for modern proteomics.

• Tofacitinib Citrate (CP-690550): Precision in JAK-STAT Immun

  2026-07-21

  Explore how Tofacitinib citrate (CP-690550 citrate) enables precision control of JAK-STAT signaling for advanced immune regulation research. This comprehensive analysis reveals new mechanistic insights and practical assay considerations for innovative inflammatory disorder models.

• Patient-Derived Gastric Cancer Assembloids Enhance Drug Test

  2026-07-21

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal cell subpopulations. The approach more accurately recapitulates tumor heterogeneity and microenvironment, enabling deeper investigation of drug responses, resistance mechanisms, and personalized therapeutic strategies.

455 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page